Trial reportGenes and immunity2005
Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis.
Trial report in Genes and immunity, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- A functional synonymous coding variant in the IL1RN gene is associated with survival in septic shock.American journal of respiratory and critical care medicine · 2014Trial
- Repurposing of drugs targeting the cytokine storm induced by SARS-CoV-2.British journal of pharmacology · 2023Review
- Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality.Pulmonary pharmacology & therapeutics · 2022Review
- Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs.The pharmacogenomics journal · 2021Review
- Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19).Clinical and translational science · 2020Review
- Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis.Biomolecules · 2020Review
- IL-1RN VNTR Polymorphism in Adult Dermatomyositis and Systemic Lupus Erythematosus.Dermatology research and practice · 2014Article
- Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.European journal of clinical pharmacology · 2013Article
- Where do we stand with the genetics of psoriatic arthritis?Current rheumatology reports · 2010Review
- Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies.Pharmacogenomics and personalized medicine · 2010Article
- Gene polymorphisms and pharmacogenetics in rheumatoid arthritis.Current genomics · 2008Article
- Contribution of single nucleotide polymorphisms of the IL1A gene to the cleavage of precursor IL-1alpha and its transcription activity.Immunogenetics · 2007Article
- Genetic epidemiology of acute respiratory distress syndrome: implications for future prevention and treatment.Clinics in chest medicine · 2006Review
- Genetic markers of treatment response in rheumatoid arthritis.Current rheumatology reports · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biological activity of the IL-1 system depends on the balance between two proinflammatory proteins (IL-1alpha and IL-1beta) and the related anti-inflammatory protein, the IL-1 receptor antagonist (IL-1Ra). The genes for these proteins lie within 430 kb on human chromosome 2. Based on a clinical trial of human recombinant IL-1ra in rheumatoid arthritis, we tested whether IL-1 genotype might be related to the likelihood of response to anti-IL-1 therapy. A positive response was defined as a reduction of at least 50% in the number of swollen joints by week 24, following treatment with either 150 mg/day IL-1ra or placebo. The response rate to treatment, independent of genotype, was 48% (44/91). A highly significant association was found between carriage of the rarer allele at IL1A(+4845) and response to treatment (P=0.0009; OR=4.85 (1.85,12.70)). The response rate in patients carrying this allele was 63.4% compared with 26.3% in noncarriers. A weaker association was found for IL1B(+3954) (P=0.02). There was a highly significant interaction between treatment (150 mg/day or placebo) and the composite genotype across IL1A(+4845) and IL1B(+3954) (P=7.6 x 10(-5)). No associations with IL-1 genotypes were found in patients receiving placebo. Thus, a significant pharmacogenomic effect was found in the treatment of RA patients with recombinant IL-1ra.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.